New on 10/15! The Science and Lived Experience of ICDs in HCM
Dr. Rachel J. Lampert, MD, a cardiac electrophysiologist and professor of medicine at Yale School of Medicine, and patient advocate Hannah Keime of HeartCharged join Dr. John Fritzlen to discuss arrhythmias, sudden cardiac death, and life after receiving an implantable cardioverter-defibrillator (ICD) in hypertrophic cardiomyopathy (HCM). The conversation covers how often patients with HCM receive ICDs and device therapy, why shock risk persists for a decade or more after implant, and how clinicians look for precipitants and structural changes before escalating treatment with beta blockers, antiarrhythmics like sotalol, catheter ablation, or cardiac denervation. Dr. Lampert shares findings from the LIVE-HCM study on vigorous exercise and arrhythmia risk, along with a structured approach for safely returning to exercise after a shock. Additionally, Hannah reflects on being shocked both in her sleep and on stage, the emotional weight of living with a device, and how adjustments to her ICD programming shaped her experience.

Watch Here

Showcase your commitment to advancing HCM research and education are while engaging directly with the clinicians and researchers driving innovation in diagnosis, treatment, and patient outcomes.

Details